Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RallybioRLYB -2.09%28 14-Day RSI is 61.53 as of Sep. 01, 2026. GuruFocus rates RLYB with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 1,422 Biotechnology companies, Rallybio ranks worse than 86.99% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-09-01), Rallybio's 14-Day RSI is 61.53.
The industry rank for Rallybio's 14-Day RSI or its related term are showing as below:
RLYB's 14-Day RSI is ranked worse than 86.99% of 1422
companies
in the Biotechnology industry
Industry Median: 48.405
vs RLYB: 61.53
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Rallybio 14-Day RSI Related Terms
RLYB vs DWTX, ALDX, ACRV: 14-Day RSI Comparison
For the Biotechnology subindustry, Rallybio's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rallybio 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rallybio's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Rallybio's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rallybio (RLYB) has a 14-Day RSI of 61.53 as of Sep. 01, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Rallybio and its competitors. According to the industry distribution chart, Rallybio ranks #1237 out of 1422 companies in the Biotechnology industry, placing it in the top 87%.
Is Rallybio's 14-Day RSI too high?
Rallybio's current 14-Day RSI is 61.53. The Biotechnology industry median 14-Day RSI is 48.41. Rallybio's value of 61.53 is 27.1% above this industry median. Based on the distribution chart, Rallybio ranks #1237 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rallybio has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Rallybio's 14-Day RSI compare to DWTX and ALDX?
According to the Biotechnology industry distribution chart, Rallybio ranks #1237 out of 1422 companies for 14-Day RSI. This places Rallybio in the lower half of its industry. The industry median 14-Day RSI is 48.41. Rallybio's value of 61.53 is 27.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.41, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rallybio's current 14-Day RSI of 61.53 is 27.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Rallybio and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rallybio's current 14-Day RSI is 61.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rallybio stock overvalued right now?
Rallybio (RLYB) has a current 14-Day RSI of 61.53. The current 14-Day RSI is 61.53 and 27.1% above the Biotechnology industry median of 48.41. Rallybio's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Rallybio (RLYB), the current 14-Day RSI is 61.53 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
28GF Score
Get the complete analysis for RLYB
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLYB has been successfully added to your 
